[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 2 of about 2
1. Huang J, Bay BH, Tan PH: Nuclear morphometry and glutathione S-transferase pi expression in breast cancer. Oncol Rep; 2000 May-Jun;7(3):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glutathione S-transferase pi (GST-pi) is a phase II detoxification enzyme whose expression is increased in estrogen receptor (ER)-poor breast cancers and in breast cancers resistant to certain chemotherapeutic agents.
  • Formalin-fixed paraffin-embedded tissue specimens obtained from 21 invasive breast cancers and 16 adjacent (benign) tissues were immunohistochemically stained using polyclonal anti-human GST-pi antibody.
  • There was positive (defined as >10% immunoreactive tumor cells) but variable expression of GST-pi in 10 (48%) cases.
  • It was also observed that GST-pi immunonegative tumor cells in GST-pi expressing tumors had different morphologies from malignant cells in the remaining 11 (52%) cancers that were regarded as GST-pi negative.
  • Increased GST-pi expression determined by the percentage of positively staining tumor cells, was found to be significantly correlated with increased variability in nuclear area and perimeter (Spearman's rho=0.821, p=0.044 for both) in the subset of node-positive tumors.
  • Our findings suggest that there exists two sub-populations of cancer cells with distinct nuclear morphologies in GST-pi positive tumors; factors other than GST-pi expression are likely to have a phenotypic effect on breast cancer cells; and there may be a special significance of this enzyme in axillary node-positive breast tumors.
  • [MeSH-minor] Breast / enzymology. Breast / pathology. Female. Humans. Isoenzymes / analysis. Lymphatic Metastasis. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis


Advertisement
2. Zhao TT, Li JG, Li YM: [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three nuclear medicine physicians analyzed the image and made the diagnosis.
  • 32 breast lesions were evaluated by histology, revealing 25 breast carcinomas and 7 benign pathological changes.
  • 23 patients had histological diagnosis of the breast tumor and regional lymph nodes.
  • But the accuracy of FDG PET/CT seems to be not high enough to identify patients who might avoid axillary lymph nodes dissection.
  • The high cost and the space resolution limit its use as a routine diagnostic method of breast cancer.
  • [MeSH-minor] Adult. Aged. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement